UY27995A1 - Nuevas formulaciones farmacéuricas solidas que comprenden telmartisano y su preparación - Google Patents

Nuevas formulaciones farmacéuricas solidas que comprenden telmartisano y su preparación

Info

Publication number
UY27995A1
UY27995A1 UY27995A UY27995A UY27995A1 UY 27995 A1 UY27995 A1 UY 27995A1 UY 27995 A UY27995 A UY 27995A UY 27995 A UY27995 A UY 27995A UY 27995 A1 UY27995 A1 UY 27995A1
Authority
UY
Uruguay
Prior art keywords
solid pharmaceutical
telmartisan
preparation
compositions
pharmaceutical formulations
Prior art date
Application number
UY27995A
Other languages
English (en)
Inventor
Dr Manabu Nakatine
Dr Toshimitsu Ohki
Sawzda Takeshi
Dr Kenzo Toyoshima
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31984063&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY27995(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of UY27995A1 publication Critical patent/UY27995A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a nuevas composiciones farmacéuticas sólidas que comprenden el antagonista del receptor e la angiotensina II telmisartano, un agente básico, un tensioactivo o emulsionante y un diluyente soluble en agua, por ejemplo, en forma de gránulos o en forma de un polvo, así como a formulaciones orales sólidas listas para usar/ingerir, por ejemplo, formulaciones en listas y comprimidos fabricadas a partir de dichas cápsulas y comprimidos fabricados a partir de dichas composiciones y farmacéuticas, y a métodos para producir dichas composiciones y formulaciones utilizando un proceso de granulación en lecho fluido o un proceso de secado por pulverización.
UY27995A 2002-09-24 2003-09-22 Nuevas formulaciones farmacéuricas solidas que comprenden telmartisano y su preparación UY27995A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10244681A DE10244681A1 (de) 2002-09-24 2002-09-24 Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung

Publications (1)

Publication Number Publication Date
UY27995A1 true UY27995A1 (es) 2004-05-31

Family

ID=31984063

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27995A UY27995A1 (es) 2002-09-24 2003-09-22 Nuevas formulaciones farmacéuricas solidas que comprenden telmartisano y su preparación

Country Status (32)

Country Link
EP (1) EP1545467B1 (es)
JP (1) JP4606166B2 (es)
KR (2) KR101107508B1 (es)
CN (2) CN101785769A (es)
AR (2) AR041370A1 (es)
AT (1) ATE372765T1 (es)
AU (1) AU2003270220B2 (es)
BR (1) BR0314687A (es)
CA (1) CA2499878C (es)
CY (1) CY1107075T1 (es)
DE (2) DE10244681A1 (es)
DK (1) DK1545467T3 (es)
EA (1) EA009237B1 (es)
EC (1) ECSP055688A (es)
ES (1) ES2294312T3 (es)
HR (1) HRP20050280B1 (es)
IL (1) IL167610A (es)
ME (1) MEP46008A (es)
MX (1) MXPA05003039A (es)
MY (1) MY136524A (es)
NO (1) NO334449B1 (es)
NZ (1) NZ539522A (es)
PE (1) PE20040418A1 (es)
PL (1) PL206396B1 (es)
PT (1) PT1545467E (es)
RS (1) RS51756B (es)
SI (1) SI1545467T1 (es)
TW (1) TWI319319B (es)
UA (1) UA81781C2 (es)
UY (1) UY27995A1 (es)
WO (1) WO2004028505A1 (es)
ZA (1) ZA200501087B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319450A1 (de) * 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Formulierung des Telmisartan Natriumsalzes
EP1586310B1 (de) * 2004-04-15 2006-12-27 Helm AG Verfahren zur Herstellung von freifliessenden, pulverförmigen Valsartan-Adsorbaten
US20060078615A1 (en) * 2004-10-12 2006-04-13 Boehringer Ingelheim International Gmbh Bilayer tablet of telmisartan and simvastatin
JP2008503595A (ja) 2004-10-15 2008-02-07 テバ ファーマシューティカル インダストリーズ リミティド テルミサルタンの調製方法
WO2006050509A2 (en) * 2004-11-03 2006-05-11 Teva Pharmaceutical Industries Ltd. Amorphous and polymorphic forms of telmisartan sodium
SI1814527T1 (sl) * 2004-11-05 2014-03-31 Boehringer Ingelheim International Gmbh Dvoslojna tableta, ki obsega telmisartan in amlodipin
US9149433B2 (en) * 2004-11-30 2015-10-06 Basf Corporation Method for formation of micro-prilled polymers
CN100370984C (zh) * 2005-03-11 2008-02-27 浙江泰利森药业有限公司 替米沙坦分散片及其制备方法
JP2009515956A (ja) * 2005-11-22 2009-04-16 テバ ファーマシューティカル インダストリーズ リミティド テルミサルタンの医薬組成物
US8637078B2 (en) * 2005-11-24 2014-01-28 Boehringer Ingelheim International Gmbh Bilayer tablet comprising telmisartan and diuretic
CA2654890C (en) 2006-06-16 2015-10-06 Lek Pharmaceuticals D.D. Pharmaceutical composition
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
EP1970053A1 (en) * 2007-03-14 2008-09-17 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical composition
FR2918277B1 (fr) * 2007-07-06 2012-10-05 Coretecholding Nouveau procede de production de formes pharmaceutiques seches hydrodispersibles et les compositions hydrodispersibles ainsi obtenues
WO2009135646A2 (en) 2008-05-05 2009-11-12 Farmaprojects, Sa Stable pharmaceutical compositions and their processes for preparation suitable for industrial scale
MX2011001150A (es) 2008-07-31 2011-03-29 Takeda Pharmaceutical Composicion farmaceutica solida.
CZ2008469A3 (cs) * 2008-07-31 2009-10-29 Zentiva, A. S. Telmisartan tablety
MX346039B (es) 2009-05-20 2017-03-03 Boehringer Ingelheim Vetmedica Gmbh Solucion farmaceutica bebible de telmisartan.
PL2443094T3 (pl) 2009-06-19 2013-08-30 Krka Tovarna Zdravil D D Novo Mesto Sposób wytwarzania telmisartanu
EP2448576A2 (en) 2009-07-02 2012-05-09 Mahmut Bilgic Solubility enhancing pharmaceutical composition
EP2448575A2 (en) 2009-07-02 2012-05-09 Bilgic Mahmut Pharmaceutical composition increasing solubility and stability
JP2011136908A (ja) * 2009-12-25 2011-07-14 Kyowa Yakuhin Kogyo Kk アンギオテンシンｉｉ受容体拮抗剤を含む固形製剤および固形製剤におけるアンギオテンシンｉｉ受容体拮抗剤の保存安定性向上方法
CA2706292A1 (en) * 2010-05-28 2011-11-28 Pharmascience Inc. A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide
WO2011161123A2 (en) 2010-06-21 2011-12-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Multilayer pharmaceutical tablet comprising telmisartan and a diuretic
TWI564008B (zh) * 2010-09-30 2017-01-01 鹽野義製藥股份有限公司 難溶性藥物之溶解性改善製劑
CN102133189B (zh) * 2011-03-18 2012-06-27 海南美兰史克制药有限公司 替米沙坦脂质体固体制剂
WO2013100112A1 (ja) * 2011-12-28 2013-07-04 ニプロ株式会社 アンギオテンシンｉｉ拮抗作用を有する化合物を含有する固形医薬組成物
EP2612658A1 (en) 2012-01-05 2013-07-10 Laboratorios Lesvi, S.L. Pharmaceutical compositions of 4'-[(1,4'dimethyl-2'-propyl[2,6'-bi-1h-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid and is 6-chloro-3,4-dihydro-2h-1,2,4-benzothiadiazine-7-sulfonamide-1,1-dioxide
WO2014068507A1 (en) 2012-11-02 2014-05-08 Abbott Healthcare Pvt. Ltd. Solid oral pharmaceutical compositions of telmisartan, essentially free of surfactants
JP6379044B2 (ja) * 2013-01-31 2018-08-22 沢井製薬株式会社 テルミサルタンとヒドロクロロチアジドとを含有する多層錠剤
JP6218664B2 (ja) * 2013-04-04 2017-10-25 沢井製薬株式会社 テルミサルタン含有錠剤
JP6344678B2 (ja) * 2013-09-27 2018-06-20 キョーリンリメディオ株式会社 テルミサルタン含有製剤及びその製造方法
CN104688696B (zh) * 2013-12-04 2017-12-19 长春海悦药业股份有限公司 一种含有坎地沙坦酯的药物组合物
JP6428340B2 (ja) * 2014-05-23 2018-11-28 ニプロ株式会社 テルミサルタンを含む医薬組成物の造粒方法
JP6440294B2 (ja) * 2014-07-01 2018-12-19 大原薬品工業株式会社 テルミサルタン含有フィルムコーティング錠剤
EP2979691A1 (en) * 2014-07-30 2016-02-03 Boehringer Ingelheim International GmbH Oral disintegrating tablet
JP6565930B2 (ja) * 2014-11-19 2019-08-28 ニプロ株式会社 口腔内崩壊錠の製造方法
JP5827428B1 (ja) * 2015-01-15 2015-12-02 日新製薬株式会社 テルミサルタン含有錠剤
CN104739833A (zh) * 2015-02-16 2015-07-01 江苏欧信医药化工有限公司 含替米沙坦和瑞舒伐他汀钙的复方双层片剂及其制备方法
JP5956034B1 (ja) * 2015-07-27 2016-07-20 エルメッド エーザイ株式会社 テルミサルタン含有医薬組成物
CN107982232A (zh) * 2018-01-29 2018-05-04 威特(湖南)药业有限公司 替米沙坦片及其制备方法
CN109350604B (zh) * 2018-11-20 2020-04-21 广州迈达康医药科技有限公司 一种替米沙坦肠溶片及其制备方法
CN110934848B (zh) * 2019-12-20 2022-02-15 江西杏林白马药业股份有限公司 一种替米沙坦胶囊及其制备方法
CN111265488B (zh) * 2020-03-18 2021-11-12 重庆康刻尔制药股份有限公司 一种替米沙坦片及其制备方法
CN112870174A (zh) * 2021-02-08 2021-06-01 天方药业有限公司 一种替米沙坦片剂的制备方法
CN115245497A (zh) * 2021-04-26 2022-10-28 武汉伯睿科医药科技有限公司 替米沙坦胶囊及其制备工艺

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
AU1042199A (en) * 1998-11-06 2000-05-29 Boehringer Ingelheim International Gmbh Antihypertensive medicaments containing lacidipine and telmisartan
AU1157500A (en) * 1998-11-06 2000-05-29 Boehringer Ingelheim International Gmbh Medicaments based on combinations of lacidipine and telmisartan or of physiological derivatives thereof
FR2787330A1 (fr) 1998-12-18 2000-06-23 Sanofi Sa Composition pharmaceutique contenant, en association, un antagoniste des recepteurs at1 de l'angiotensine ii et un immunosuppresseur pour la prevention ou le traitement des complications vasculaires du rejet de greffe
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
JP2001139461A (ja) * 1999-11-10 2001-05-22 Ohta Pharmaceut Co Ltd 速崩壊性錠剤
JP2001278812A (ja) * 2000-03-27 2001-10-10 Kyoto Pharmaceutical Industries Ltd 錠剤用崩壊剤及びこれを用いた錠剤
PT1467712E (pt) * 2002-01-16 2008-01-09 Boehringer Ingelheim Pharma Comprimido farmacêutico de duas camadas compreendendo telmisartan e hidroclorotiazida

Also Published As

Publication number Publication date
AU2003270220A1 (en) 2004-04-19
JP2006502194A (ja) 2006-01-19
PL374347A1 (en) 2005-10-17
EP1545467A1 (en) 2005-06-29
WO2004028505A1 (en) 2004-04-08
PT1545467E (pt) 2007-11-27
DE10244681A1 (de) 2004-04-08
ECSP055688A (es) 2005-05-30
NO20050688L (no) 2005-03-23
EA009237B1 (ru) 2007-12-28
TWI319319B (en) 2010-01-11
SI1545467T1 (sl) 2008-02-29
KR20050053690A (ko) 2005-06-08
CA2499878C (en) 2012-03-13
CN101785769A (zh) 2010-07-28
BR0314687A (pt) 2005-08-02
MY136524A (en) 2008-10-31
AR087239A2 (es) 2014-03-12
PL206396B1 (pl) 2010-08-31
RS51756B (sr) 2011-12-31
DE60316323T2 (de) 2008-01-17
CY1107075T1 (el) 2012-10-24
PE20040418A1 (es) 2004-08-16
DK1545467T3 (da) 2007-11-05
KR101107508B1 (ko) 2012-01-31
MEP46008A (en) 2011-02-10
DE60316323D1 (de) 2007-10-25
HRP20050280A2 (en) 2006-05-31
NO334449B1 (no) 2014-03-03
MXPA05003039A (es) 2005-05-27
EA200500405A1 (ru) 2005-10-27
HRP20050280B1 (hr) 2014-01-03
AR041370A1 (es) 2005-05-11
TW200418463A (en) 2004-10-01
ATE372765T1 (de) 2007-09-15
AU2003270220B2 (en) 2009-06-04
KR101188650B1 (ko) 2012-10-09
CN1684665A (zh) 2005-10-19
EP1545467B1 (en) 2007-09-12
ES2294312T3 (es) 2008-04-01
RS20050239A (en) 2007-06-04
NZ539522A (en) 2006-10-27
IL167610A (en) 2009-02-11
ZA200501087B (en) 2006-11-29
KR20110122882A (ko) 2011-11-11
UA81781C2 (uk) 2008-02-11
JP4606166B2 (ja) 2011-01-05
CA2499878A1 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
UY27995A1 (es) Nuevas formulaciones farmacéuricas solidas que comprenden telmartisano y su preparación
PE20061449A1 (es) Composiciones farmaceuticas comprendiendo imatinib y un retardador de liberacion
ECSP055568A (es) Composición de comprimido de liberación sostenida de pramipexol
MY139086A (en) Use of debranched starch in extrusion-spheronization pharmaceutical pellets
TW200800998A (en) Phenylalanine derivatives
AR065809A1 (es) Formulaciones farmaceuticas que contienen un inhibidor sglt2
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
WO2009043844A3 (en) Orodispersible tablets
WO2006011159A3 (en) Stabilized pharmaceutical composition containing rabeprazole sodium with improved bioavailability
EA200701816A1 (ru) Продукты, включающие микрокапсулы с быстрым высвобождением
RU2014115287A (ru) Фармацевтическая композиция для перорального введения с маскированным вкусом и способ ее получения
RS54329B1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING RIFAXIMINE, PROCEDURES FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF VAGINAL INFECTIONS
AR100977A1 (es) Formulación compuesta para la administración oral que comprende ezetimiba y rosuvastatina, y un proceso para su preparación
UA116334C2 (uk) Тверді форми дозування бендамустину
BR112016026667A8 (pt) comprimido oralmente desintegrante para administração de avanafil, métodos associados de fabricação e uso de um inibidor de pde v
PH12015500823A1 (en) Modified release formulations for oprozomib
WO2007129019A8 (en) Sulfonamide compounds useful as edg receptor modulators
WO2010026467A3 (en) Controlled release tablet of a highly water soluble active agent such as levetiracetam, or citicoline
JP2013530153A (ja) 医薬品工業における珪藻土の新規な用途
UA95274C2 (ru) Твердый фармацевтический препарат, содержащий ирбесартан, и способы его изготовления
AR025879A1 (es) Granulaciones de celulosa hidrolizada de sales de farmacos
ATE508737T1 (de) Clopidogrel-hydrogensulfat von polymorph 1 form enthaltende pharmazeutische zusammensetzung
RU2016106328A (ru) Противотуберкулезная стабильная фармацевтическая композиция в форме диспергируемой таблетки, содержащей гранулированный изониазид и гранулированный рифапентин, и способ ее приготовления
BRPI1010987B8 (pt) composições de dosagem sólida de liberação controlada contendo ibuprofeno

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150504